Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← Zenuzolac
reduces riskIncreased
risk →
reduces riskIncreased
risk →
Zenuzolac for COVID-19
1
study with
90
patients
Serious outcome risk
No significant improvements are seen in meta-analysis to date.
COVID-19 Zenuzolac studies · November 2026
|
Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← Zenuzolac
reduces riskIncreased risk → |
Apr 11 2025 |
et al., NCT04590547 | Safety, Tolerability and Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection |
| 200% higher mortality (p=0.34), 1% worse recovery (p=0.99), and 1% shorter hospitalization (p=0.87). RCT 132 hospitalized COVID-19 patients showing no significant difference in outcomes with zenuzolac (GLS-1027) treatment. | ||
